Biopharma Veteran Ted Schroeder Joins Phathom’s Board to Fuel Growth

Phathom Pharmaceuticals has welcomed a seasoned name in biotech, Ted Schroeder, to its Board of Directors during a crucial time in the company’s journey. With more than 30 years of experience driving innovation and commercial success in the biopharma world, Schroeder’s leadership is expected to bolster Phathom’s next phase of growth—particularly as it ramps up the momentum around its lead therapy, VOQUEZNA®. His expertise in bringing novel treatments to market and navigating key strategic transitions adds a powerful dimension to Phathom’s boardroom.

Michael Cola, Chairman of the Board, shared his enthusiasm about the appointment, calling Schroeder “a growth-focused visionary with a history of building lasting impact.” As Phathom sharpens its focus on expanding access to first-in-class GI therapies, Schroeder’s insight into commercialization and company scaling is anticipated to play a pivotal role. His addition to the board signals a continued commitment to innovation, patient impact, and delivering value to shareholders in an evolving therapeutic landscape.